Search for Clinical Trial Results
Adenocarcinoma of the Appendix - 23 Studies Found
Status | Study |
Recruiting |
Study Name: Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis Condition: Noninvasive Mucinous Cystadenocarcinoma of Ovary Date: 2014-04-22 Interventions: Other: A sampling of blood A sampling of blood de 14 ml |
Recruiting |
Study Name: Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei Condition: Gastrointestinal Neoplasms Date: 2013-09-12 Interventions: Behavioral: Questionnaire Completion of 3 questionnaires a |
Recruiting |
Study Name: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis Condition: Cancer Date: 2015-04-14 Interventions: Drug: systemic chemotherapy twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks af |
Completed |
Study Name: Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Condition:
|
Active, not recruiting |
Study Name: Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Condition:
|
Terminated |
Study Name: Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Condition:
Interventions: Drug: Ethanol and Paclitaxel Injection Endoscopic ultrasound will be used to locate and assess the pancr |
Completed |
Study Name: Edrecolomab in Treating Patients With Stage II Colon Cancer Condition:
|
Recruiting |
Study Name: Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage Condition:
Interventions: |
Not yet recruiting |
Study Name: Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC) Date: 2016-04-22 Interventions:
|
Recruiting |
Study Name: A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Condition: HER2/Neu+ Uterine Serous Carcinoma Date: 2015-07-02 Interventions: Drug: Afatinib Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 |